Id., at 4, 11, 12, 13 (“There may be a fundamental difference in the kind of uncertainty associated with nanoscale materials compared to conventional chemicals, both with respect to knowledge about them and the way testing is performed.”);
id., at 15 (“Also as discussed above, there may be general differences in properties relevant to evaluation of safety and effectiveness (as applicable) of products using nanoscale materials compared to products using other materials.”);
id., at 17 (“[B]ecause many of these tests were developed for molecular forms of materials, and nanoscale materials may behave differently, the ability of these tests to support decisions about biological effects or further testing requirements need to be evaluated.”);
id., at 18 (“Currently, ability to detect nanoscale materials in the body or in products regulated by FDA is limited and…may require substantial effort.”);
id., at 18 (“[M]aterials in the nanoscale range may present particular challenges, for example relating to tests that assess product stability or development of potentially hazardous byproducts.”);
id., at 18 (“Standard approaches for handling materials for testing will also need to be evaluated and may need to be modified.”);
id., at 20 (“As discussed in the State of the Science section, the Task Force believes that nanoscale materials will present regulatory challenges that are similar to those posed by other new technologies that FDA has dealt with in the past, such as biotechnology products, but also some potentially new challenges.”);
id., at 30 ('As discussed in the State of the Science section, although the science of nanotechnology is continuing to evolve, it is known that the size of a particle can affect its properties such that versions of the same substance with differing particle sizes can have different properties…. To appropriately assess the safety…it will be important in some cases for FDA or the manufacturer to take into account whether the product contains nanoscale materials.”);
id., at 32 (Because nanoscale materials can behave differently than other versions of the same materials, it will be important for FDA to obtain relevant information about the characteristics of products containing nanoscale materials.”);
id., at 32 (“[T]he presence of nanoscale materials may change the regulatory status/regulatory pathway of products.”)
Google Scholar